Cabaletta Bio to Present at Jefferies Virtual Healthcare Conference
Rhea-AI Summary
Cabaletta Bio, a clinical-stage biotechnology company, announced that Dr. Steven Nichtberger will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 3:30 p.m. ET. A live webcast of the event will be available on their website, with a replay accessible for 90 days. The company is focused on engineered T cell therapies for B cell-mediated autoimmune diseases, leveraging their Cabaletta Approach to selectively eliminate specific B cells while preserving normal ones. Their lead candidate, DSG3-CAART, targets mucosal pemphigus vulgaris.
Positive
- None.
Negative
- None.
News Market Reaction – CABA
On the day this news was published, CABA gained 8.92%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
PHILADELPHIA, May 27, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President, Chief Executive Officer and Co-Founder, will participate in a fireside chat at the upcoming Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020, at 3:30 p.m. ET.
A live webcast of the presentation will be available on the News and Events section of the company’s website at www.cabalettabio.com. Following the presentation, a replay of the webcast will be available on the website for 90 days.
About Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is entering clinical development as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The company’s lead preclinical product candidate, MuSK-CAART, is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
Investors:
Sarah McCabe
Stern Investor Relations, Inc.
sarah.mccabe@sternir.com
FAQ
When is Cabaletta Bio's participation in the Jefferies Virtual Healthcare Conference?
How can I watch the Cabaletta Bio presentation at the Jefferies Conference?
What is Cabaletta Bio's focus in biotechnology?
What is the lead product candidate of Cabaletta Bio?
What technologies does Cabaletta Bio utilize for treatment?
